Q4 2025 Management View Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results presented ...
At the AD/PD 2026, Roche showcased new five-year data from the Phase II PASADENA trial (NCT03100149) involving prasinezumab.
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...
Lyell Immunopharma, Inc. is rated a Buy, with upside contingent on replicating clinical superiority in larger trials. Learn ...
Q4 2025 Earnings Call March 24, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman ...
NÖK Therapeutics, Inc. ('NÖK” or the 'Company”), a clinical-stage biotechnology company advancing autologous Natural Killer ( ...
A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and ...
A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and ...
Morning Overview on MSN
New Apogee Therapeutics data reveal long-acting eczema drug cuts flares with fewer shots
Apogee Therapeutics is advancing APG777, an experimental antibody designed to treat moderate-to-severe atopic dermatitis with far fewer injections than existing biologics. Early clinical data show the ...
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with ...
Elevation Marketing reports the healthcare software market, valued at $84 billion, grows rapidly while hospitals make ...
Deepfake images can mislead viewers, upend elections, and instigate violence. They can also, researchers say, disrupt medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results